Published in Drug Week, February 13th, 2004
In addition, the company also announced that Vogel will serve on the board's audit and compensation committees. Vogel will fill the new Class II vacancy created by the unanimous decision by the company's board to expand its size from five to six members. The term for Class II members is set to expire at the 2004 annual meeting of stockholders.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.